Abstract:mg of citalopram prior to the start of the central nervous system stable isotope labeling kinetics study of Abeta, as previously described. A lumbar catheter was placed and hourly sampling of blood and CSF was conducted during and after administration of a stable-isotope labeled amino acid (13C6-leucine). Metabolism of Abeta was measured using stable isotope labeling kinetics (SILK-Ab ) assay (as in Bateman et al., 2006) with the addition of stable isotope spike absolute quantitation (SISAQ ) to allow for quantitation of Abeta concentrations (C2N Diagnostics). Results: Placebo (n1⁄4 9) and citalopram (n1⁄4 11) treated subjects did not differ on any demographic variables. Citalopram-treated subjects had significantly lower mean total Abeta concentrations (36.7 +/10.5) ng/mL than placebo-treated (54.6 +/15.5) ng/mL (p 1⁄4 0.007) over the hours 5-36. During the same period there was a trend towards lower newly generated Abeta (p 1⁄4 0.06) in the citalopram group (7.5 +/1.3) ng/mL vs placebo (9.3 +/1.4) ng/mL however the groups did not differ in their fractional synthesis or clearance rates.Conclusions:We corroborate our prior findings in a prospective human study showing that citalopram lowers Abeta concentrations compared with placebo. We had also expected to see a lower rate of Abeta production and a decrease in newly generated Abeta, thus we are currently replicating and extending our results. The ability to decrease Abeta concentrations is potentially important as a preventive strategy for AD.

Pre-Symptomatic Functional Brain Changes in Ps1 E280a Mutation Carriers Compared to Other Biomarkers: Pilot Data from the Alzheimer'S Prevention Initiative Biomarker Project